Dave Lennon, former president of Novartis Gene Therapies

Zol­gens­ma patent spat brews be­tween No­var­tis and Re­genxbio as top No­var­tis gene ther­a­py ex­ec de­parts

Re­genxbio, a small li­cen­sor of gene ther­a­py vi­ral vec­tors spun out from the Uni­ver­si­ty of Penn­syl­va­nia, is now find­ing it­self in the mid­dle of some ma­jor league patent fights.

In ad­di­tion to a patent suit with Sarep­ta Ther­a­peu­tics from last Sep­tem­ber, No­var­tis is now try­ing to push its small­er part­ner out of the way. The Swiss bio­phar­ma li­censed Re­genxbio’s AAV9 vec­tor for its $2.1 mil­lion spinal mus­cu­lar at­ro­phy ther­a­py Zol­gens­ma.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.